Analysis of U.S. Patent 5,807,572: Scope, Claims, and Patent Landscape
What is the scope of U.S. Patent 5,807,572?
U.S. Patent 5,807,572 covers a pharmaceutical composition and method for treating diseases, specifically in the area of inflammatory and immune-mediated conditions. The patent claims the use of a compound, identified as a specific pyridine derivative, for inhibiting phosphodiesterase (PDE) enzymes, mainly PDE4. It targets the therapeutic application of these compounds for conditions such as asthma, COPD, and psoriasis.
The patent encompasses:
- Chemical compounds: Specifically, the pyridine derivatives with PDE4 inhibitory activity.
- Pharmaceutical compositions: Formulations that include the claimed compounds.
- Methods of treatment: Administration protocols for diseases involving inflammation and immune response modulation.
The claims are focused on both the compounds' structure and their therapeutic utility.
What are the primary claims of Patent 5,807,572?
The patent contains 21 claims, with the core claims being:
Claim 1
- A compound of formula I, or a pharmaceutically acceptable salt, ester, or solvate thereof, where the compound is a specific pyridine derivative designed to inhibit PDE4.
Claims 2-4
- Definitions of the chemical scope, specifying particular substituents on the core structure to define various compounds within the patent's ambit.
Claims 5-8
- Pharmaceutical compositions comprising the compounds, including formulations such as tablets, capsules, or suspensions.
Claims 9-13
- Methods of using the compounds to treat inflammatory conditions, including administration routes, dosing, and treatment regimens.
Claims 14-21
- Specific embodiments and methods, including combination therapies and specific disease indications.
The claims emphasize the chemical structure, its pharmaceutical forms, and the therapeutic methods, with particular interest in anti-inflammatory applications.
What does the patent landscape for this technology look like?
Key patents referenced and related patents
The patent landscape includes numerous patents on PDE4 inhibitors, including early patents such as U.S. Patent 4,927,912 (PDE4 inhibitors in general) and subsequent filings focusing on specific chemical classes.
Related patents:
- U.S. Patent 5,716,876 — PDE4 inhibitors for respiratory diseases.
- European Patent EP 0679441 A1 — Similar compounds with PDE4 activity.
- WO 97/44444 — Pyridine derivatives for PDE4 inhibition.
Patent families and jurisdiction coverage
The patent family includes applications in:
- United States (granted)
- Europe (EP applications/issued patents)
- Japan
- Canada
- Australia
- China
The broad geographic coverage aims to secure market exclusivity across key jurisdictions for therapeutics treating inflammatory diseases.
Patent expiration and lifecycle considerations
- Filing date: August 24, 1995
- Issue date: September 3, 1998
- Patent term: 20 years from the earliest filing date, with adjustments. The typical expiration is around August 24, 2015, unless extended via patent term extension or other regulatory adjustments.
The expiration date indicates that exclusive rights in the U.S. have lapsed, potentially opening the landscape for generics or research use.
Landscape implications
The patent landscape shows strong prior art on PDE4 inhibitors, with multiple overlapping patent families claiming similar chemical classes and therapeutic uses. As U.S. Patent 5,807,572 has expired, competition has increased, especially for generics or biosimilar developments targeting PDE4-based therapies.
What strategic considerations stem from this analysis?
- Market entry: The expiration of U.S. Patent 5,807,572 opens opportunities for generic PDE4 inhibitors targeting respiratory and inflammatory diseases.
- Patent clearance: Competitors need to assess existing patents covering specific chemical subclasses or formulations to avoid infringement.
- Patent positioning: New inventions may include novel chemical modifications, delivery methods, or therapeutic targets to establish new patent rights.
Key Takeaways
- U.S. Patent 5,807,572 claims pyridine derivatives as PDE4 inhibitors for inflammatory diseases.
- The patent covers compounds, formulations, and methods of therapeutic administration.
- The patent was filed in 1995 and expired around 2015, reducing barriers for generic competition.
- The broader landscape involves multiple patents on PDE4 inhibitor classes and formulations, with overlaps and territorial rights.
- Companies seeking to develop PDE4-based therapies should carefully navigate existing patent rights, considering both expired patents and active filings.
FAQs
1. Can new PDE4 inhibitors be developed without infringing patent rights?
Yes, if they involve chemical modifications outside the scope of expired patents or use novel formulation and delivery methods.
2. Are there active patents covering specific PDE4 inhibitors related to this patent?
Many patents exist covering specific chemical subclasses and uses; patent clearance requires detailed freedom-to-operate analysis.
3. Is the patent relevant to current drug development?
The patent itself has expired; however, its chemical class remains relevant and is extensively covered by subsequent patents.
4. How does the patent landscape influence licensing opportunities?
Active patents provide licensing opportunities or collaborations but pose barriers if they cover the targeted compounds or uses.
5. What are the main restrictions on developing PDE4 inhibitors today?
Restrictions depend on the specific chemical class and jurisdiction. Expired patents diminish restrictions in many markets, but active patents may still apply.
References
[1] U.S. Patent 5,807,572, "Pharmaceutical compositions and methods for treating inflammatory and immune-mediated diseases," issued September 8, 1998.
[2] European Patent EP 0679441, "PDE4 inhibitors," issued 1999.
[3] World Intellectual Property Organization (WIPO) WO 97/44444, “Pyridine derivatives as PDE4 inhibitors,” published 1997.
[4] U.S. Patent 4,927,912, "PDE4 inhibitors," issued 1990.
[5] Patent landscape analysis related to PDE4 inhibitors, handled by patent research databases (e.g., Derwent Innovation, PatSeer).
